By Daniella Parra Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) said it completed a $4.1 million private placement of shares and warrants to existing stockholders. The company said it aims to develop new biologic medicines to improve patient access and...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it appointed Peter Powchik, M.D. as Executive Vice President, Global Scientific Director overseeing its scientific direction and lead development efforts. Powchik was previously Senior Vice President at Regeneron Pharmaceuticals, the company said....

By Daniella Parra Plus Therapeutics (Nasdaq: PSTV) said it appointed Dr. Pius Maliakal as VP of Clinical Operations. With over 20 years of global oncology experience, he will lead key clinical initiatives, advancing the ReSPECT-GBM and ReSPECT-LM trials for central...

By Daniella Parra Octave Bioscience said it secured a $30 million extension to its Series B funding round. The investment, led by Novartis, Hikma Ventures and Intermountain Ventures, will accelerate commercialization of their precision care solution for multiple sclerosis (MS)...

By Daniella Parra Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) announced a strategic partnership with Quality Chemical Laboratories, Inc. to manufacture Comera’s lead SQore excipients. Comera’s SQore platform transforms intravenously administered biologics into patient-delivered subcutaneous formulations, the company said in...

By Daniella Parra Avertix Medical announced that Professor Ian Meredith AM will join the Board of Directors, bringing extensive experience as a renowned interventional cardiologist and global medical executive, the company said. “Avertix has a meaningful product that holds the...

By Daniella Parra Promontory Therapeutics, a clinical stage pharmaceutical company focused on oncology, said it treated its first four patients in France for late-stage metastatic castration-resistant prostate cancer (mCRPC). The study is being led by oncologist Dr. Karim Fizazi at...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA), announced the successful completion of a private placement transaction, generating approximately $8.7 million. The notes, bearing a 6.0% annual interest rate and maturing in July 2028, can be converted into Eterna common...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) announced positive Phase 1 clinical trial results for their investigational immunotherapeutic, UB-312, in Parkinson’s disease patients. The data showed that the antibodies effectively engage with aggregated alpha-synuclein, a toxic protein associated with PD,...

By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) said it plans to conduct a clinical trial comparing its precision oral appliance therapy and hypoglossal nerve stimulation for severe obstructive sleep apnea treatment. This follows positive preliminary data from a study that...